Why Pfizer's Bad Outlook Doesn't Matter

In this video, health-care analyst David Williamson takes a closer look at Pfizer's first-quarter results and guidance reduction. Diving past the headlines, investors need to look to the future when valuing the potential of this Big Pharma.

Watch and get a succinct breakdown of the first quarter and find out what critical catalysts are coming for Pfizer investors in the near future.

What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Editor's note: Xeljanz has not been officially rejected in Europe, but it did recently receive a negative opinion from the European Medicines Agency.

The article Why Pfizer's Bad Outlook Doesn't Matter originally appeared on Fool.com.

David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.